OptimizeRx Corporation OPRX is gaining from strong demand across its pharmaceutical client base, expanding relationships with both large and mid-tier customers, and increasing adoption of its Dynamic Audience Activation Platform (DAAP). The company’s disciplined cost management and post-acquisition efficiencies have strengthened profitability.
A key pillar of the company’s financial profile is its improving cash strength, supported by strong operating execution and a scalable, largely fixed-cost structure. OptimizeRx has demonstrated its ability to translate revenue growth into meaningful profitability, with adjusted EBITDA more than doubling year over year.
Operating cash flow increased significantly to $18.7 million in 2025 from $4.9 million in the prior year, while free cash flow from operations reached nearly $19 million. The company also strengthened its balance sheet, ending the year with $23.4 million in cash and short-term investments, up from $13.4 million a year earlier, even after paying down $8 million in debt. This robust cash generation underscores the company’s financial flexibility, enabling it to fund strategic initiatives, reduce leverage and consider shareholder returns such as its recently authorized $10 million share repurchase program.
OptimizeRx has reaffirmed its focus on adjusted EBITDA, raising its guidance to a range of $21 million to $25 million for 2026 from the previously indicated $19 million to $22 million. Despite a softer revenue outlook and some near-term uncertainty, management continues to prioritize operating efficiency and margin discipline. The company also anticipates a back-half-weighted performance, with stronger momentum expected later in the year as market conditions stabilize and customer spending trends improve.
That said, OptimizeRx is facing several near-term headwinds. The company is experiencing softness in contracted revenue, primarily due to a shift away from managed services, which had contributed meaningfully in the prior year. Additionally, pharmaceutical clients are adopting a more cautious spending approach in early 2026 as they navigate most favored nation (MFN) pricing dynamics. This has led to shorter contract durations and a temporary pause in marketing spend across both direct-to-consumer and healthcare provider channels. These factors are expected to weigh on near-term growth, particularly in the first half of the year.
Nevertheless, OptimizeRx’s strong cash position and disciplined execution position it well to navigate near-term headwinds and drive a recovery.
Let’s Look at the Performance of Competitors
Phreesia PHR reported a solid improvement in its cash position and overall liquidity in fiscal 2026, supported by strong operating performance. Net cash provided by operating activities rose significantly to $78.8 million from $32.4 million in fiscal 2025, reflecting better earnings quality and working capital management. Free cash flow also increased to $54.4 million from $8.3 million, highlighting enhanced cash generation. In the fourth quarter alone, operating cash flow reached $33.7 million, with free cash flow of $28.5 million. Despite this strength, total cash, cash equivalents and restricted cash was $73.8 million at year-end, slightly lower year over year.
Veeva Systems Inc. VEEV remains well-positioned as a long-term winner in life sciences digitalization, supported by strong execution, deep customer trust and a broad, integrated product portfolio. The company is investing steadily in innovation, embedding AI across applications to enhance automation and long-term value creation. Veeva Systems is well capitalized, having exited the fourth quarter of fiscal 2026 with cash and cash equivalents and investments of $6.56 billion. Cumulative net cash provided by operating activities at the end of the quarter was $1.42 billion compared with $1.09 billion a year ago. The company finished the fiscal fourth quarter with no debt on its balance sheet. For the fiscal first quarter, the company expects total revenues between $855 million and $858 million.
OPRX Price Performance, Valuation & Estimates
Shares of OptimizeRx have lost 39.8% in the past three months compared with the Computer Software industry’s decline of 8.1%.
Image Source: Zacks Investment Research
Regarding the forward 12-month price/sales ratio, OPRX is trading at 1.18, lower than the sector’s multiple of 7.12.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OPRX’s earnings for fiscal 2027 has been revised upward over the past 60 days.
Image Source: Zacks Investment Research
OPRX currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See Stocks Now >>OptimizeRx Corp. (OPRX) : Free Stock Analysis Report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
Phreesia, Inc. (PHR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
